Vilnius-based Atrandi Biosciences has secured $25 million in Series A funding, with Lux Capital leading the round alongside Vsquared Ventures, Practica Capital, Metaplanet, and GRIDS Capital. The company develops single-cell sample preparation technology, using semipermeable capsules to enable precise molecular analysis while preserving single-cell resolution. The funding will support Atrandi’s expansion into the US market, further development of its microfluidic platforms, and the launch of new products. Atrandi previously raised $4.8 million in 2023 and now plans to open a Boston office as part of its growth strategy.
Atrandi Biosciences is a biotechnology company focused on single-cell sample preparation and microfluidic technologies. Originally founded as Droplet Genomics in 2016, the company develops semipermeable capsule (SPC) technology, which allows researchers to analyze single cells while maintaining high-throughput capabilities. Atrandi offers platforms such as Flux, Styx, and Onyx, used in applications ranging from microbial genomics to fluorescence-based cell detection. With a team of over 65 employees, the company is expanding its operations, including plans to establish a Boston office as it grows its presence in the US market.
“Lithuania is a well-kept secret on the biotech scene,” Atrandi CEO Juozas Nainys told Andrew Dunn from Endpointnews. “There’s this vibe of what I imagine Silicon Valley was maybe 50, 60 years ago, or maybe in the early 2000s.”
Hey there! I’m a writer and editor who thrives on coffee, curiosity, and the occasional cat snuggle. I’m based in the beautiful Aegean region, and I adopt vegan lifestyle. When I’m not busy digging into the latest startup news or polishing up someone’s manuscript, you’ll find me curled up with a good book or playing games while enjoying the company of my beloved cats.
